Liverpool ChiroChem (LCC), the specialist Liverpool-based chemical intermediates company, has raised £1.5m in equity finance to support the Company’s growth plans and increase production capacity overseas. The new fundraise round was led by Praetura Capital and the Northern Powerhouse Investment Fund (NPIF), and supported by long standing investor Deepbridge Capital.

The Company, originally a spin-out from Liverpool University, has the capability to produce exceptionally pure chemical forms using its own patented technology and has already established itself firmly within the pharmaceutical and drug discovery supply chain. Founded just three years ago, it counts over 70 pharma, biotech and agrochemicals customers including Merck, Novartis, Domainex, Syngenta and Bayer.